Bourne Lent Asset Management Inc. held its stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,604 shares of the medical equipment provider’s stock at the end of the second quarter. Bourne Lent Asset Management Inc.’s holdings in Boston Scientific Corporation were worth $433,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank boosted its stake in Boston Scientific Corporation by 56.7% in the first quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock worth $9,150,000 after buying an additional 133,121 shares in the last quarter. Koch Industries Inc. purchased a new stake in Boston Scientific Corporation during the first quarter worth $307,000. Bellevue Group AG boosted its stake in Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after buying an additional 22,000 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Boston Scientific Corporation by 1.7% in the first quarter. Principal Financial Group Inc. now owns 1,983,944 shares of the medical equipment provider’s stock worth $49,340,000 after buying an additional 33,763 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Boston Scientific Corporation by 63.8% in the first quarter. Morgan Stanley now owns 3,744,380 shares of the medical equipment provider’s stock worth $93,124,000 after buying an additional 1,458,906 shares in the last quarter. Institutional investors and hedge funds own 91.87% of the company’s stock.

Shares of Boston Scientific Corporation (NYSE:BSX) traded down 0.40% on Friday, hitting $27.62. The company’s stock had a trading volume of 4,648,524 shares. The stock’s 50 day moving average is $27.76 and its 200-day moving average is $25.65. The company has a market cap of $37.82 billion, a price-to-earnings ratio of 88.53 and a beta of 1.10. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.30 by $0.01. Boston Scientific Corporation had a return on equity of 23.45% and a net margin of 5.07%. The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.08 billion. During the same quarter in the previous year, the firm posted $0.28 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.25 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Bourne Lent Asset Management Inc. Holds Position in Boston Scientific Corporation (BSX)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/07/23/bourne-lent-asset-management-inc-holds-position-in-boston-scientific-corporation-bsx.html.

A number of equities research analysts recently weighed in on BSX shares. Stifel Nicolaus upped their price target on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “hold” rating in a report on Wednesday, June 28th. BidaskClub lowered Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, April 24th. Guggenheim reaffirmed a “buy” rating on shares of Boston Scientific Corporation in a research note on Wednesday, April 12th. Finally, Jefferies Group LLC upped their target price on Boston Scientific Corporation from $26.00 to $28.00 and gave the company a “hold” rating in a research note on Friday, April 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $29.61.

In other Boston Scientific Corporation news, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the transaction, the chief financial officer now directly owns 235,421 shares in the company, valued at approximately $6,469,369.08. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP David A. Pierce sold 10,250 shares of Boston Scientific Corporation stock in a transaction that occurred on Wednesday, April 26th. The stock was sold at an average price of $26.00, for a total transaction of $266,500.00. Following the transaction, the senior vice president now owns 35,850 shares in the company, valued at $932,100. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 243,579 shares of company stock worth $6,590,050. Corporate insiders own 0.74% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.